Ardelyx Stock Plummets As Review Period For Tenapanor US Application Pushed By 3 Months

by Vandana Singh, Benzinga Editor

April 30, 2021 6:34 AM | 1 min read | Make a Comment

The FDA has extended the Prescription Drug User Fee Act (PDUFA) date for Ardelyx Inc's ARDX tenapanor for the control of serum phosphorus in adult patients with chronic kidney disease (CKD) on dialysis.
The agency asked the company to submit additional analyses to help the FDA better understand the clinical data in light of tenapanor's novel mechanism of action as compared to approved therapies.
In response, the company submitted the requested analyses, resulting in an extension of the PDUFA date by three months to July 29, 2021.
Price Action: ARDX shares drop 19% at $6.83 in the premarket session on the last check Friday.

Posted In: Biotech News Health Care Small Cap FDA General Briefs Chronic Kidney Disease

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.